Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Ectopia Lentis: Causes, Symptoms, and Management
Ectopia lentis is a term that holds a pivotal place within the realm of ophthalmology, shedding light on a unique condition that involves the lens of the eye. This condition, characterized by the displacement or dislocation of the lens from…
What Is Bullous Keratopathy and How to Manage It
What Is Bullous Keratopathy? Bullous keratopathy (BK) is a pathological condition characterized by the presence of fluid-filled blisters or “bullae” on the cornea, which is the clear front surface of the eye. The main underlying factor leading to the formation…
LumiThera Receives $2.3M NIH Grant for Dry AMD Trial
LumiThera has been granted a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH), totaling up to $2.3 million in funding over a span of 2 years. This NIH/NEI grant is geared towards supporting…
What Is Endophthalmitis and How to Manage It
What Is Endophthalmitis? Endophthalmitis is a rare but serious eye condition that can lead to vision loss if not promptly treated. This infection targets the interior structures of the eye, causing inflammation and potential damage. Understanding the symptoms, causes, treatment…
What Is Corneal Opacity? | OBN
Corneal opacity refers to the clouding or loss of transparency in the cornea, the clear, dome-shaped front part of the eye. It can significantly impair vision and lead to various visual disturbances. This comprehensive article aims to provide a detailed…
Comprehensive Eye Drop Recall List for 2023
Since February 2023, the FDA and various companies have been actively initiating recalls of eye drops and ointments due to concerns about potential bacterial contamination. The recalls, motivated by the risk of tainted products, have been steadily increasing, underscoring the…
Astellas Signs Ophthalmic Gene Therapy Deal with 4DMT
Astellas Pharma has signed a license agreement that grants them the rights to utilize the intravitreal retinotropic R100* vector, developed by 4D Molecular Therapeutics (4DMT). This agreement enables Astellas to target one specific genetic target associated with rare monogenic ophthalmic…
Waterloo University’s Drug for AMD and DME
Researchers have successfully developed a groundbreaking synthetic protein to treat macular degeneration and other currently incurable eye diseases leading to blindness in millions of individuals. This pioneering drug, currently undergoing human trials, is the first of its kind. With over…
What Is Bull’s Eye Maculopathy and How to Manage It
What Is Bull’s Eye Maculopathy? Bull’s Eye Maculopathy is a specific form of retinal disease characterized by changes in the pigmentation of the macular region of the retina, often presenting as a ‘bull’s eye’ pattern. The macula is the central…
SYFOVRE® Secures Permanent J-Code from CMS
The U.S. Centers for Medicare & Medicaid Services (CMS) have officially designated a specific J-code (J2781) for Apellis Pharmaceuticals’ Syfovre (pegcetacoplan injection), marking it as the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. This J-code for…